Clinical studies found that Procysbi was statistically as effective as Cystagon. While there were some adverse effects, Raptor Pharmaceutical Corp. (NASDAQ:RPTP) reported that no serious unexpected issues emerged that were attributable to Procysbi.
Although the FDA pushed back its decision on Procysbi from January to April, that shouldn’t raise concerns about the drug’s chances. Delays of three months aren’t unusual.
Analysts see annual sales for Procysbi of around $150 million. Considering that Raptor’s current market cap is less than $360 million on no revenue, a positive decision by the FDA should make the stock take off.
We still have to wait a few days to find out what will happen, so whether Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares sink or soar is anyone’s guess at this point. It’s a tough call on how well Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s efforts on Juxtapid fared during the first quarter. I think things could have gone either way.
While anything can happen with FDA decisions, I expect Raptor Pharmaceutical Corp. (NASDAQ:RPTP) will receive good news by next week. A positive FDA announcement would mean even better news to the families with loved ones suffering from nephropathic cystinosis.
The article 2 Orphan Drugmakers With Upcoming Catalysts originally appeared on Fool.com and is written by Keith Speights.
Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.